Ozdemir, GulsahGulhan, BoraSukur, Eda Didem KurtAtayar, EmineAtan, RaziyeDursun, IsmailOzcakar, Zeynep Birsin2024-08-042024-08-0420230041-4301https://doi.org/10.24953/turkjped.2022.735https://search.trdizin.gov.tr/yayin/detay/1186276https://hdl.handle.net/11616/9272753rd Annual Meeting of European-Society-for-Pediatric-Nephrology (ESPN) -- SEP 16-19, 2021 -- Amsterdam, NETHERLANDSBackground. Alport syndrome (AS) is characterized by progressive kidney disease. There is increasing evidence that renin-angiotensin-aldosterone system (RAAS) inhibition delays chronic kidney disease (CKD) while the effectiveness of immunosuppressive (IS) therapy in AS is still uncertain. In this study, we aimed to analyze the outcomes of pediatric patients with X-linked AS (XLAS) who received RAAS inhibitors and IS therapy.Methods. Seventy-four children with XLAS were included in this multicenter study. Demographic features, clinical and laboratory data, treatments, histopathological examinations, and genetic analyses were analyzed retrospectively.Results. Among 74 children, 52 (70.2%) received RAAS inhibitors, 11 (14.9%) received RAAS inhibitors and IS, and 11 (14.9%) were followed up without treatment. During follow-up, glomerular filtration rate (GFR) decreased <60 ml/min/1.73 m2 in 7 (9.5%) of 74 patients (M/F=6/1). In male patients with XLAS, kidney survival was not different between RAAS and RAAS+IS groups (p=0.42). The rate of progression to CKD was significantly higher in patients with nephrotic range proteinuria and nephrotic syndrome (NS), respectively (p=0.006, p=0.05). The median age at the onset of RAAS inhibitors was significantly higher in male patients who progressed to CKD (13.9 vs 8.1 years,Conclusions. RAAS inhibitors have beneficial effects on proteinuria and early initiation of therapy may delay the progression to CKD in children with XLAS. There was no significant difference between the RAAS and RAAS+IS groups in kidney survival. AS patients presenting with NS or nephrotic range proteinuria should be followed upeninfo:eu-repo/semantics/openAccessAlport syndromecyclosporin Aimmunosuppressive therapynephrotic syndromeRAAS inhibitorsConference Object6534564683739596510.24953/turkjped.2022.7352-s2.0-85164209626Q31186276WOS:001025408400011Q4